State of the art in developing allergen vaccines in Cuba: prospects of novel adjuvanted vaccines.
Standardized allergen vaccines have been developed and registered as biopharmaceutical products in Cuba. Three different vaccines were obtained from the most relevant allergenic mite species: Dermatophagoides pteronvssinus, Dermatophagoides siboney, and Blomia tropicalis. Immuno-analytical methods based on murine monoclonal antibodies and human IgE antibodies were developed for assessing allergenic potency, composition, and stability. Preclinical and clinical studies showed efficacy and safety in diagnostic prick-tests and subcutaneous immunotherapy in asthmatic patients. New approaches are now undertaken in order to develop new adjuvanted formulations based on liposomes or proteoliposomes from Neisseria meningitidis, and purified allergens; aiming to overcome the drawbacks of conventional immunotherapy.
Labrada
Alexis
A
Allergens Department, Centro Nacional de Biopreparados, P.O. Bor 6048, Havana 10600, Cuba. labrada@biocen.cu
Facenda
Elisa
E
Castro
Raul L
RL
Fernández
Bárbara
B
Uyema
Keiko
K
Sewer
Minerva
M
Aranda
Rosa E
RE
Más
Arelis
A
Navarro
Bárbara
B
Jorge
Olga
O
Novoa
Ivette
I
Díaz
José
J
Bourg
Virgilio
V
D000276:Adjuvants, Immunologic; D000485:Allergens / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology* / Q000302:isolation & purification; D000818:Animals; D003462:Cuba; D003888:Desensitization, Immunologic / Q000009:adverse effects; D008081:Liposomes / Q000494:pharmacology; D051379:Mice; D008925:Mites / Q000276:immunology*; D009345:Neisseria meningitidis; D011510:Proteolipids / Q000494:pharmacology; D014612:Vaccines / Q000276:immunology / Q000627:therapeutic use
D000276:Adjuvants, Immunologic; D000485:Allergens; D008081:Liposomes; D011510:Proteolipids; D014612:Vaccines; C020485:proteoliposomes